The best LDL-cholesterol reduction can be achieved by inhibiting cholesterol absorption (i.e., by fitosterols, green tea) and cholesterol synthesis (i.e., by statins, red yeast rice, policosanols) . The objective of our study, conducted in patients with mild-moderate cardiovascular risk, was to assess the effect of 8 weeks of non pharmacological treatment based on association of milk-based drink enriched with 2 g plant sterols (Pro-Activ, one mini-drink after dinner) plus a nutraceutical (Colestat) containing mainly red yeast rice (a fungal fermentation product of Monascus purpureus containing 3 mg of lovastatin), policosanols (10 mg) and green tea (144 mg) (one tablet at bed-time). The association therapy was initiated in 24 patients (15 males, 9 females, age range 38-64 years) with an average cardiovascular risk at 10 years of 13.6 and with moderate hypercholesterolemia (total cholesterol >239 mg/dL) in spite of treatment with Pro-Activ (13 patients) and Colestat (11 patients) used in monotherapy for 8 weeks. Compared to monotherapy, TC and LDL-C levels were significantly reduced with the combination therapy to reach the TC and LDL-C goals in the majority of these patients (<240 and <160 mg/dL, respectively, reached in 21/24 patients). Moreover, the cardiovascular risk also has been reduced to reach the level of 10.7 (-21.3% versus monotherapy). No undesired effects were recorded. In conclusion, this association could represent an effective non-pharmacological therapeutic approach in patients with moderate hypercholesterolemia at mild-moderate cardiovascular risk.

The third natural road to fight hypercholesterolemia / Volpe, R; Gavita, R; Grassi, Maria Caterina; Pille, J.. - In: ATHEROSCLEROSIS SUPPLEMENTS. - ISSN 1567-5688. - STAMPA. - 10:(2009), pp. e1471-e1471. (Intervento presentato al convegno XV International Symposium on Atherosclerosis tenutosi a Boston, MA, USA nel June 14-18, 2009).

The third natural road to fight hypercholesterolemia

GRASSI, Maria Caterina;
2009

Abstract

The best LDL-cholesterol reduction can be achieved by inhibiting cholesterol absorption (i.e., by fitosterols, green tea) and cholesterol synthesis (i.e., by statins, red yeast rice, policosanols) . The objective of our study, conducted in patients with mild-moderate cardiovascular risk, was to assess the effect of 8 weeks of non pharmacological treatment based on association of milk-based drink enriched with 2 g plant sterols (Pro-Activ, one mini-drink after dinner) plus a nutraceutical (Colestat) containing mainly red yeast rice (a fungal fermentation product of Monascus purpureus containing 3 mg of lovastatin), policosanols (10 mg) and green tea (144 mg) (one tablet at bed-time). The association therapy was initiated in 24 patients (15 males, 9 females, age range 38-64 years) with an average cardiovascular risk at 10 years of 13.6 and with moderate hypercholesterolemia (total cholesterol >239 mg/dL) in spite of treatment with Pro-Activ (13 patients) and Colestat (11 patients) used in monotherapy for 8 weeks. Compared to monotherapy, TC and LDL-C levels were significantly reduced with the combination therapy to reach the TC and LDL-C goals in the majority of these patients (<240 and <160 mg/dL, respectively, reached in 21/24 patients). Moreover, the cardiovascular risk also has been reduced to reach the level of 10.7 (-21.3% versus monotherapy). No undesired effects were recorded. In conclusion, this association could represent an effective non-pharmacological therapeutic approach in patients with moderate hypercholesterolemia at mild-moderate cardiovascular risk.
2009
XV International Symposium on Atherosclerosis
hypercholesterolemia; Agents affecting cholesterol absorption; Agents affecting cholesterol synthesis; Neutraceuticals; Clinical trials
04 Pubblicazione in atti di convegno::04c Atto di convegno in rivista
The third natural road to fight hypercholesterolemia / Volpe, R; Gavita, R; Grassi, Maria Caterina; Pille, J.. - In: ATHEROSCLEROSIS SUPPLEMENTS. - ISSN 1567-5688. - STAMPA. - 10:(2009), pp. e1471-e1471. (Intervento presentato al convegno XV International Symposium on Atherosclerosis tenutosi a Boston, MA, USA nel June 14-18, 2009).
File allegati a questo prodotto
Non ci sono file associati a questo prodotto.

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11573/467860
 Attenzione

Attenzione! I dati visualizzati non sono stati sottoposti a validazione da parte dell'ateneo

Citazioni
  • ???jsp.display-item.citation.pmc??? ND
  • Scopus ND
  • ???jsp.display-item.citation.isi??? 0
social impact